Status:
COMPLETED
Severe Alcohol-use Disorder: a tDCS and Response Inhibition Training Intervention
Lead Sponsor:
Brugmann University Hospital
Collaborating Sponsors:
University Ghent
Université Libre de Bruxelles
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Most severe forms of alcohol-use disorder are thought to reflect an abnormal interplay between two neural systems: an overly active impulsive one driven by immediate rewards prospects and a weak refle...
Detailed Description
Treating Alcohol dependence remains notoriously difficult despite use of several medications, psychotherapeutic and psychosocial interventions. Alcohol dependence is thought to reflect an abnormal int...
Eligibility Criteria
Inclusion
- Patients with severe alcohol-use disorder (DSM-5 criteria), hospitalized for detoxification.
- Severity of alcohol use disorder must be at least moderate (at least 4 DSM-5 criteria)
- Aged between 18 and 65 years
- Comorbidity with anxiety disorders and depressive disorders is allowed
- Patients must be illegal drug free for 3 weeks at beginning of trial
- Pharmacotherapy: patients should be benzodiazepines free at the moment of inclusion. They are allowed to continue other psychotropic medication (antidepressants, antipsychotics, mood stabilizers), providing they are following a stable regimen that will not be changed during the protocol time.
- Patients must be reachable for follow-up
Exclusion
- Previous neurological conditions (epilepsy, traumatic brain injury, stroke)
- Present delirium, confusion or severe cognitive disorder
- Schizophrenia, chronic psychotic disorders, bipolar type 1 disorder.
- Any severe, life-threatening disorders
- High suicidal risk
- Specific contraindications for tDCS: metallic plates in the head
- Alcohol medication treatment initiated during the rehab: acamprosate, disulfiram, baclofen, nalmefen.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT03447054
Start Date
January 1 2018
End Date
September 1 2020
Last Update
November 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU-Brugmann
Brussels, Belgium, ++32